Zobrazeno 1 - 9
of 9
pro vyhledávání: '"Brad Screnci"'
Autor:
Joseph Rucker, Rachel H. Fong, Tabb Sullivan, Carmen Navia, Brad Screnci, Rona Wilf, Benjamin J. Doranz
Publikováno v:
Cancer Research. 83:2646-2646
Rigorous specificity analysis is critical for the development of antibody-based therapies, as even minimal off-target binding can lead to toxicity and clinical failures. Long believed to be exquisitely specific, recent preclinical data and our own wo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::cdec5dca593a7da126c4c78ab976761d
https://doi.org/10.1158/1538-7445.am2023-2646
https://doi.org/10.1158/1538-7445.am2023-2646
Autor:
Brad Screnci, Lewis J. Stafford, Trevor Barnes, Kristen Shema, Samantha Gilman, Rebecca Wright, Suzie Al Absi, Tim Phillips, Charles Azuelos, Katherine Slovik, Paige Murphy, Daniel B. Harmon, Tom Charpentier, Benjamin J. Doranz, Joseph B. Rucker, Ross Chambers
Publikováno v:
iScience. 25:105665
The tight junction protein claudin 6 (CLDN6) is differentially expressed on cancer cells with almost no expression in healthy tissue. However, achieving therapeutic MAb specificity for this 4 transmembrane protein is challenging because it is nearly
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::41f45f33f9be0c7261fdfc5bb530829c
https://doi.org/10.1016/j.isci.2022.105665
https://doi.org/10.1016/j.isci.2022.105665
Autor:
Brad Screnci, Trevor Barnes, Kristen Shema, Rebecca Rimkunas, Shruthi Kannan, Tim Phillips, Carmen Navia, Charles Azuelos, Tom Charpentier, Jennifer Houtmann, Lisa Miller, Lewis J. Stafford, Benjamin J. Doranz, Joseph B. Rucker, Ross Chambers
Publikováno v:
Cancer Research. 82:317-317
Monoclonal antibodies (MAbs) are a well-established treatment approach in oncology and other diseases. Nevertheless, many multipass membrane proteins are largely inaccessible as antibody targets due to their poor expression, membrane-dependent struct
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::29e5a2fdaee7e481f65c8ce1e940a67b
https://doi.org/10.1158/1538-7445.am2022-317
https://doi.org/10.1158/1538-7445.am2022-317
Autor:
Brad Screnci, Lewis J. Stafford, Trevor Barnes, Kristen Shema, Samantha Gilman, Rebecca Rimkunas, Suzie Al Absi, Tim Phillips, Charles Azuelos, Katherine Slovik, Paige Muprhy, Daniel B. Harmon, Tom Charpentier, Benjamin J. Doranz, Joseph B. Rucker, Ross Chambers
Publikováno v:
Cancer Research. 82:318-318
The tight junction protein Claudin 6 (CLDN6) is differentially expressed on cancer cells with almost no expression in healthy tissue, making it a valuable therapeutic target for many solid tumor cancers. Despite their potential as cancer therapeutics
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1b9670879b2f7035b9c6bcb9c756c4f3
https://doi.org/10.1158/1538-7445.am2022-318
https://doi.org/10.1158/1538-7445.am2022-318
Autor:
Nicholas Molino, Chidananda Sulli, Benjamin J. Doranz, Lewis J. Stafford, Erin Rosenberg, Tom Charpentier, Ross Chambers, David F. Tucker, Joseph Rucker, Brad Screnci
Publikováno v:
Diabetes. 68
Integral membrane proteins are important drug targets, and monoclonal antibodies (mAbs) against them are highly sought for therapeutic and diagnostic purposes. However, the complex structure of multipass membrane proteins makes discovery of these mAb
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c1caa2784f51922aa6c0b4e56b2e766b
https://doi.org/10.2337/db19-1177-p
https://doi.org/10.2337/db19-1177-p
Autor:
Rona Wilf, David F. Tucker, Sharon H. Willis, Joseph Rucker, Samantha Gilman, Tanmayee Hazarika, Ross Chambers, Jonathan Tabb Sullivan, Brad Screnci, Nicholas Molino, Trevor Barnes, Chidananda Sulli, Charpentier Thomas, Jennifer M. Pfaff, Erin Rosenberg, Rebecca Rimkunas, Benjamin J. Doranz, Lewis J. Stafford
Publikováno v:
Cancer Research. 78:5759-5759
Claudin 6 (CLDN6) is a tight junction molecule that is involved in cell to cell adhesion of epithelial and endothelial cell sheets. CLDN6 is considered an oncofetal protein which is not expressed in normal human tissue but is expressed in some cancer
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b8950bf5dadc16c9ba60c3d50c151a78
https://doi.org/10.1158/1538-7445.am2018-5759
https://doi.org/10.1158/1538-7445.am2018-5759
Autor:
Yu-Hung Huang, Gabriela L. Cosma, Vitali Alexeev, Gregory E. Gonye, Charles J. Yeo, Janet A. Sawicki, Brad Screnci, Jonathan R. Brody, Aristeidis G. Telonis, Fernando F. Blanco, Masaya Jimbo, Jordan M. Winter
Publikováno v:
Oncotarget
Post-transcriptional regulation is a powerful mediator of gene expression, and can rapidly alter the expression of numerous transcripts involved in tumorigenesis. We have previously shown that the mRNA-binding protein HuR (ELAVL1) is elevated in huma
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d9d874c40f9d9c640db79281bcd22a63
https://pubmed.ncbi.nlm.nih.gov/26314962
https://pubmed.ncbi.nlm.nih.gov/26314962
Autor:
David F. Tucker, Sharon H. Willis, Ross Chambers, Lewis J. Stafford, Rachel H. Fong, Trevor Barnes, Nicholas Molino, Moniquetta Hall, Andrew Ettenger, Chidananda Sulli, Benjamin J. Doranz, Jennifer M. Pfaff, Brad Screnci, Andrew Hudacek, Joseph Rucker, Manu Mabila
Publikováno v:
Cancer Research. 77:74-74
The objective of this work was to evaluate the ability to generate panels of monoclonal antibodies against a set of highly challenging targets including GPCRs (CB1, C5AR, CXCR5 and CGRPR), transporters (GLUT4), and ion channels (P2X3). Integral membr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3be5b1c6989a99fd01e8d24e8227b0c3
https://doi.org/10.1158/1538-7445.am2017-74
https://doi.org/10.1158/1538-7445.am2017-74
Autor:
Charles J. Yeo, Yu-Hung Huang, Jordan M. Winter, Brad Screnci, Jonathan R. Brody, Masaya Jimbo, Janet A. Sawicki, Vitali Alexeev, Gabriela L. Cosma, Fernando F. Blanco
Publikováno v:
Cancer Research. 75:5133-5133
Background: Pancreatic ductal adenocarcinoma (PDA) is the fourth most common cause of cancer-related death in the Unites States, with an overall 5-year survival rate of Methods: Stable MiaPaCa2 cell lines were generated that produce two different shR
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e3f26d94b5607a38fdb77ce31e517db4
https://doi.org/10.1158/1538-7445.am2015-5133
https://doi.org/10.1158/1538-7445.am2015-5133